NCT04412863Phase 2Completed

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Study sponsor: Vir Biotechnology, Inc. · VIR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-03-25Actual

Enrollment · participants84Actual

Source updated2026-04-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chronic Hepatitis B

Treatments or interventions studied

VIR-2218DrugAlso known as Elebsiran
pegylated interferon-alfa 2aDrugAlso known as pegylated interferon alpha-2a, PEG-IFNα

Primary outcomes · main study measures

measure: Number of Subjects With Adverse Events as Assessed by CTCAE v5.0; timeFrame: Up to 148 Weeks; measure: Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory Findings; timeFrame: Up to 148 Weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history